References analysis of the Wikipedia article "CDKN2A" in the English version

doi.org

Mega JL, Stitziel NO, Smith JG, Chasman DI, Caulfield M, Devlin JJ, Nordio F, Hyde C, Cannon CP, Sacks F, Poulter N, Sever P, Ridker PM, Braunwald E, Melander O, Kathiresan S, Sabatine MS (June 2015). "Genetic risk, coronary heart disease events, and the clinical benefit of statin therapy: an analysis of primary and secondary prevention trials". Lancet. 385 (9984): 2264–2271. doi:10.1016/S0140-6736(14)61730-X. PMC 4608367. PMID 25748612.

Aoude LG, Wadt KA, Pritchard AL, Hayward NK (March 2015). "Genetics of familial melanoma: 20 years after CDKN2A". Pigment Cell & Melanoma Research. 28 (2): 148–60. doi:10.1111/pcmr.12333. PMID 25431349. S2CID 5341669.

Byeon IJ, Li J, Ericson K, Selby TL, Tevelev A, Kim HJ, O'Maille P, Tsai MD (February 1998). "Tumor suppressor p16INK4A: determination of solution structure and analyses of its interaction with cyclin-dependent kinase 4". Molecular Cell. 1 (3): 421–31. doi:10.1016/s1097-2765(00)80042-8. PMID 9660926.

Lo D, Zhang Y, Dai MS, Sun XX, Zeng SX, Lu H (March 2015). "Nucleostemin stabilizes ARF by inhibiting the ubiquitin ligase ULF". Oncogene. 34 (13): 1688–97. doi:10.1038/onc.2014.103. PMC 4212020. PMID 24769896.

Karayan L, Riou JF, Séité P, Migeon J, Cantereau A, Larsen CJ (February 2001). "Human ARF protein interacts with topoisomerase I and stimulates its activity". Oncogene. 20 (7): 836–48. doi:10.1038/sj.onc.1204170. PMID 11314011. S2CID 2801461.

Kanellou P, Zaravinos A, Zioga M, Spandidos DA (June 2009). "Deregulation of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in basal cell carcinoma". The British Journal of Dermatology. 160 (6): 1215–21. doi:10.1111/j.1365-2133.2009.09079.x. PMID 19298278. S2CID 29291218.

Chen D, Kon N, Li M, Zhang W, Qin J, Gu W (July 2005). "ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor". Cell. 121 (7): 1071–83. doi:10.1016/j.cell.2005.03.037. PMID 15989956. S2CID 16176749.

Miao L, Song Z, Jin L, Zhu YM, Wen LP, Wu M (February 2010). "ARF antagonizes the ability of Miz-1 to inhibit p53-mediated transactivation". Oncogene. 29 (5): 711–22. doi:10.1038/onc.2009.372. PMID 19901969.

Eymin B, Leduc C, Coll JL, Brambilla E, Gazzeri S (March 2003). "p14ARF induces G2 arrest and apoptosis independently of p53 leading to regression of tumours established in nude mice" (PDF). Oncogene. 22 (12): 1822–35. doi:10.1038/sj.onc.1206303. PMID 12660818.

Mason SL, Loughran O, La Thangue NB (June 2002). "p14(ARF) regulates E2F activity". Oncogene. 21 (27): 4220–30. doi:10.1038/sj.onc.1205524. PMID 12082609. S2CID 8866243.

Rayess H, Wang MB, Srivatsan ES (April 2012). "Cellular senescence and tumor suppressor gene p16". International Journal of Cancer. 130 (8): 1715–25. doi:10.1002/ijc.27316. PMC 3288293. PMID 22025288.

Takahashi A, Ohtani N, Yamakoshi K, Iida S, Tahara H, Nakayama K, Nakayama KI, Ide T, Saya H, Hara E (November 2006). "Mitogenic signalling and the p16INK4a-Rb pathway cooperate to enforce irreversible cellular senescence". Nature Cell Biology. 8 (11): 1291–7. doi:10.1038/ncb1491. PMID 17028578. S2CID 8686894.

Witkiewicz AK, Knudsen KE, Dicker AP, Knudsen ES (August 2011). "The meaning of p16(ink4a) expression in tumors: functional significance, clinical associations and future developments". Cell Cycle. 10 (15): 2497–503. doi:10.4161/cc.10.15.16776. PMC 3685613. PMID 21775818.

Kelley MJ, Nakagawa K, Steinberg SM, Mulshine JL, Kamb A, Johnson BE (May 1995). "Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines". Journal of the National Cancer Institute. 87 (10): 756–61. doi:10.1093/jnci/87.10.756. PMID 7563154.

Hayward NK (May 2003). "Genetics of melanoma predisposition". Oncogene. 22 (20): 3053–62. doi:10.1038/sj.onc.1206445. PMID 12789280. S2CID 20268281.

McPherson R, Pertsemlidis A, Kavaslar N, Stewart A, Roberts R, Cox DR, Hinds DA, Pennacchio LA, Tybjaerg-Hansen A, Folsom AR, Boerwinkle E, Hobbs HH, Cohen JC (June 2007). "A common allele on chromosome 9 associated with coronary heart disease". Science. 316 (5830): 1488–91. Bibcode:2007Sci...316.1488M. doi:10.1126/science.1142447. PMC 2711874. PMID 17478681.

Ye S, Willeit J, Kronenberg F, Xu Q, Kiechl S (July 2008). "Association of genetic variation on chromosome 9p21 with susceptibility and progression of atherosclerosis: a population-based, prospective study". Journal of the American College of Cardiology. 52 (5): 378–84. doi:10.1016/j.jacc.2007.11.087. PMID 18652946.

Huang Q, Su X, Ai L, Li M, Fan CY, Weiss LM (October 2007). "Promoter hypermethylation of multiple genes in gastric lymphoma". Leukemia & Lymphoma. 48 (10): 1988–96. doi:10.1080/10428190701573224. PMID 17852707. S2CID 72186314.

Robaina MC, Faccion RS, Arruda VO, de Rezende LM, Vasconcelos GM, Apa AG, Bacchi CE, Klumb CE (February 2015). "Quantitative analysis of CDKN2A methylation, mRNA, and p16(INK4a) protein expression in children and adolescents with Burkitt lymphoma: biological and clinical implications". Leukemia Research. 39 (2): 248–56. doi:10.1016/j.leukres.2014.11.023. PMID 25542698.

Asokan GS, Jeelani S, Gnanasundaram N (October 2014). "Promoter hypermethylation profile of tumour suppressor genes in oral leukoplakia and oral squamous cell carcinoma". Journal of Clinical and Diagnostic Research. 8 (10): ZC09-12. doi:10.7860/JCDR/2014/9251.4949. PMC 4253256. PMID 25478438.

Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D (January 2007). "K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking". Pancreas. 34 (1): 55–62. doi:10.1097/01.mpa.0000246665.68869.d4. PMC 1905887. PMID 17198183.

Marchetti A, Buttitta F, Pellegrini S, Bertacca G, Chella A, Carnicelli V, Tognoni V, Filardo A, Angeletti CA, Bevilacqua G (February 1997). "Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas". The Journal of Pathology. 181 (2): 178–82. doi:10.1002/(SICI)1096-9896(199702)181:2<178::AID-PATH741>3.0.CO;2-5. PMID 9120722. S2CID 20155703.

Qureshi MA, Jan N, Dar NA, Hussain M, Andrabi KI (September 2012). "A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population". Biomarkers. 17 (6): 552–6. doi:10.3109/1354750X.2012.699556. PMID 22724384. S2CID 19678492.

He D, Zhang YW, Zhang NN, Zhou L, Chen JN, Jiang Y, Shao CK (April 2015). "Aberrant gene promoter methylation of p16, FHIT, CRBP1, WWOX, and DLC-1 in Epstein-Barr virus-associated gastric carcinomas". Medical Oncology. 32 (4): 92. doi:10.1007/s12032-015-0525-y. PMID 25720522. S2CID 38800637.

Rajendran P, Dashwood WM, Li L, Kang Y, Kim E, Johnson G, Fischer KA, Löhr CV, Williams DE, Ho E, Yamamoto M, Lieberman DA, Dashwood RH (2015-01-01). "Nrf2 status affects tumor growth, HDAC3 gene promoter associations, and the response to sulforaphane in the colon". Clinical Epigenetics. 7 (1): 102. doi:10.1186/s13148-015-0132-y. PMC 4575421. PMID 26388957.

Bhagat R, Kumar SS, Vaderhobli S, Premalata CS, Pallavi VR, Ramesh G, Krishnamoorthy L (September 2014). "Epigenetic alteration of p16 and retinoic acid receptor beta genes in the development of epithelial ovarian carcinoma". Tumour Biology. 35 (9): 9069–78. doi:10.1007/s13277-014-2136-1. PMID 24913706. S2CID 1766337.

Ameri A, Alidoosti A, Hosseini SY, Parvin M, Emranpour MH, Taslimi F, Salehi E, Fadavip P (December 2011). "Prognostic Value of Promoter Hypermethylation of Retinoic Acid Receptor Beta (RARB) and CDKN2 (p16/MTS1) in Prostate Cancer". Chinese Journal of Cancer Research = Chung-Kuo Yen Cheng Yen Chiu. 23 (4): 306–11. doi:10.1007/s11670-011-0306-x. PMC 3551302. PMID 23358881.

Tsao H, Niendorf K (November 2004). "Genetic testing in hereditary melanoma". Journal of the American Academy of Dermatology. 51 (5): 803–8. doi:10.1016/j.jaad.2004.04.045. PMID 15523363.

Kefford R, Bishop JN, Tucker M, Bressac-de Paillerets B, Bianchi-Scarrá G, Bergman W, Goldstein A, Puig S, Mackie R, Elder D, Hansson J, Hayward N, Hogg D, Olsson H (November 2002). "Genetic testing for melanoma". The Lancet. Oncology. 3 (11): 653–4. doi:10.1016/s1470-2045(02)00894-x. PMID 12424065.

Bishop DT, Demenais F, Goldstein AM, Bergman W, Bishop JN, Bressac-de Paillerets B, Chompret A, Ghiorzo P, Gruis N, Hansson J, Harland M, Hayward N, Holland EA, Mann GJ, Mantelli M, Nancarrow D, Platz A, Tucker MA (June 2002). "Geographical variation in the penetrance of CDKN2A mutations for melanoma". Journal of the National Cancer Institute. 94 (12): 894–903. doi:10.1093/jnci/94.12.894. PMID 12072543.

Krishnamurthy J, Torrice C, Ramsey MR, Kovalev GI, Al-Regaiey K, Su L, Sharpless NE (November 2004). "Ink4a/Arf expression is a biomarker of aging". The Journal of Clinical Investigation. 114 (9): 1299–307. doi:10.1172/JCI22475. PMC 524230. PMID 15520862.

Hernandez-Segura A, de Jong TV, Melov S, Guryev V, Campisi J, Demaria M (September 2017). "Unmasking Transcriptional Heterogeneity in Senescent Cells". Current Biology. 27 (17): 2652–2660.e4. Bibcode:2017CBio...27E2652H. doi:10.1016/j.cub.2017.07.033. PMC 5788810. PMID 28844647.

Shearin AL, Hedan B, Cadieu E, Erich SA, Schmidt EV, Faden DL, Cullen J, Abadie J, Kwon EM, Gröne A, Devauchelle P, Rimbault M, Karyadi DM, Lynch M, Galibert F, Breen M, Rutteman GR, André C, Parker HG, Ostrander EA (July 2012). "The MTAP-CDKN2A locus confers susceptibility to a naturally occurring canine cancer". Cancer Epidemiology, Biomarkers & Prevention. 21 (7): 1019–27. doi:10.1158/1055-9965.EPI-12-0190-T. PMC 3392365. PMID 22623710.

nih.gov

pubmed.ncbi.nlm.nih.gov

Huang Y, Tyler T, Saadatmandi N, Lee C, Borgstrom P, Gjerset RA (July 2003). "Enhanced tumor suppression by a p14ARF/p53 bicistronic adenovirus through increased p53 protein translation and stability". Cancer Research. 63 (13): 3646–53. PMID 12839954.

Mason SL, Loughran O, La Thangue NB (June 2002). "p14(ARF) regulates E2F activity". Oncogene. 21 (27): 4220–30. doi:10.1038/sj.onc.1205524. PMID 12082609. S2CID 8866243.

Li Y, Nichols MA, Shay JW, Xiong Y (December 1994). "Transcriptional repression of the D-type cyclin-dependent kinase inhibitor p16 by the retinoblastoma susceptibility gene product pRb". Cancer Research. 54 (23): 6078–82. PMID 7954450.

Hayward NK (May 2003). "Genetics of melanoma predisposition". Oncogene. 22 (20): 3053–62. doi:10.1038/sj.onc.1206445. PMID 12789280. S2CID 20268281.

El-Naggar AK, Lai S, Clayman G, Lee JK, Luna MA, Goepfert H, Batsakis JG (December 1997). "Methylation, a major mechanism of p16/CDKN2 gene inactivation in head and neck squamous carcinoma". The American Journal of Pathology. 151 (6): 1767–74. PMC 1858347. PMID 9403727.

Tsao H, Niendorf K (November 2004). "Genetic testing in hereditary melanoma". Journal of the American Academy of Dermatology. 51 (5): 803–8. doi:10.1016/j.jaad.2004.04.045. PMID 15523363.

ncbi.nlm.nih.gov

ghr.nlm.nih.gov

"CDKN2A". Genetics Home Reference. National Library of Medicine. January 2015. Retrieved April 14, 2015.

semanticscholar.org

api.semanticscholar.org

Mason SL, Loughran O, La Thangue NB (June 2002). "p14(ARF) regulates E2F activity". Oncogene. 21 (27): 4220–30. doi:10.1038/sj.onc.1205524. PMID 12082609. S2CID 8866243.

Hayward NK (May 2003). "Genetics of melanoma predisposition". Oncogene. 22 (20): 3053–62. doi:10.1038/sj.onc.1206445. PMID 12789280. S2CID 20268281.

CDKN2A (English Wikipedia)

biogps.org

cancer.gov

doi.org

ensembl.org

May2017.archive.ensembl.org

genecards.org

harvard.edu

ui.adsabs.harvard.edu

inserm.fr

hal.inserm.fr

nih.gov

pubmed.ncbi.nlm.nih.gov

ncbi.nlm.nih.gov

ghr.nlm.nih.gov

semanticscholar.org

api.semanticscholar.org

uniprot.org

zenodo.org